Transporter
VMAT2
Vesicular monoamine transporter 2
- GeneSLC18A2
- FamilyVesicular transporters
A cDNA for a rat vesicular monoamine transporter, which the paper calls MAT, was isolated in 1992 by expression cloning in a mammalian cell line. It predicts a protein of 515 amino acids with 12 putative membrane-spanning domains. In digitonin-permeabilized cells the uptake of serotonin was ATP dependent. Reserpine was the most potent inhibitor of uptake, followed by tetrabenazine, serotonin, dopamine, norepinephrine and epinephrine, and serotonin was the preferred substrate. The messenger RNA was present specifically in monoamine-containing cells of the locus coeruleus, substantia nigra and raphe nucleus of the rat brain.1 It packs monoamines from the cytoplasm into synaptic vesicles against a very large concentration gradient. The energy comes from the proton gradient made by the vesicular H+-ATPase, and each amine molecule is exchanged for two protons.2 Two isoforms exist. VMAT1 is found in endocrine and paracrine cells of the intestine, stomach and sympathetic nervous system, whereas VMAT2 is found in neurons of the sympathetic, enteric and central nervous systems and in some endocrine cells, among them a subset of adrenal chromaffin cells and cells of the stomach. In the endocrine and paracrine populations of stomach, intestine and sympathetic nervous system the two isoforms are mutually exclusive.3
In the brain it is present in all monoaminergic neurons, those with dopamine, serotonin, noradrenaline, adrenaline and histamine. It is probably also the vesicular transporter of the neurons that make trace amines such as tyramine and phenylethylamine, for which receptors are now known. It is also found in the beta cells of the pancreas.4,2
Reserpine and tetrabenazine block it. Tetrabenazine inhibits it reversibly, depletes dopamine more than noradrenaline and binds most densely in the caudate nucleus, the putamen and the nucleus accumbens. Reserpine binds irreversibly to both VMAT1 and VMAT2, so its action lasts much longer.5 Tetrabenazine was the first drug approved in the United States for the chorea of Huntington disease. In a trial with 54 treated and 30 placebo patients, chorea fell by 5.0 units on a scale from 0 to 28 under tetrabenazine and by 1.5 under placebo. Depression is common in Huntington disease and can be made worse by the drug, and one suicide occurred in a patient on tetrabenazine in the double-blind study.5
Mice without VMAT2 are born but die within a few days. They move little and feed poorly, and their brains hold far less monoamine, although the monoamine cell groups and their projections look normal.6,7 Adult mice with only one working copy have less dopamine outside the cells in the striatum and release less dopamine when stimulated by potassium or amphetamine. They are supersensitive to the movement-stimulating effect of apomorphine, cocaine, amphetamine and ethanol.6 In cultures from the mutant mice, amphetamine but not depolarisation induced dopamine release. In living mutant animals amphetamine increased movement, promoted feeding and prolonged survival. The authors conclude that exocytotic release is not needed for certain complex behaviours and that VMAT2 is not essential for amphetamine action.7
In isolated chromaffin granules, amphetamine, cocaine and phencyclidine, which are weak bases, reduced the pH gradient of the vesicles, which reduced the uptake and increased the release of transmitter. A review presents VMAT2 as a target that enables the rewarding and addictive actions of amphetamine and cocaine, in addition to the plasma membrane transporter DAT.8,4 Measuring the density of VMAT2 by PET has been clinically useful for early diagnosis and for following the progression of Parkinson's disease, Alzheimer's disease and drug addiction.2
Sources (8)
- Erickson et al. 1992Erickson JD, Eiden LE, Hoffman BJ (1992) Expression cloning of a reserpine-sensitive vesicular monoamine transporter Proc Natl Acad Sci U S A
- Wimalasena 2011Wimalasena K (2011) Vesicular monoamine transporters: structure-function, pharmacology, and medicinal chemistry Med Res Rev
- Weihe et al. 1994Weihe E, Schäfer MK, Erickson JD, et al. (1994) Localization of vesicular monoamine transporter isoforms (VMAT1 and VMAT2) to endocrine cells and neurons in rat J Mol Neurosci
- Eiden et al. 2011Eiden LE, Weihe E (2011) VMAT2: a dynamic regulator of brain monoaminergic neuronal function interacting with drugs of abuse Annals of the New York Academy of Sciences
- Frank 2010Frank S (2010) Tetrabenazine: the first approved drug for the treatment of chorea in US patients with Huntington disease Neuropsychiatr Dis Treat
- Wang et al. 1997Wang YM, Gainetdinov RR, Fumagalli F, et al. (1997) Knockout of the vesicular monoamine transporter 2 gene results in neonatal death and supersensitivity to cocaine and amphetamine Neuron
- Fon et al. 1997Fon EA, Pothos EN, Sun BC, et al. (1997) Vesicular transport regulates monoamine storage and release but is not essential for amphetamine action Neuron
- Sulzer et al. 1990Sulzer D, Rayport S (1990) Amphetamine and other psychostimulants reduce pH gradients in midbrain dopaminergic neurons and chromaffin granules: a mechanism of action Neuron
Functional potency (EC₅₀)
1 substance, 1 displayed value. Strongest first within each organism. Emax is shown where the paper reports it. Efficacy depends on the assay and its reference agonist.
Human
1 measurement
Butylone4400 nMEshleman et al. 2013
- Assay
- permeabilised HEK-293 cells expressing human VMAT2, release of preloaded [3H]noradrenaline
- Shown value from
- Eshleman et al. 2013, Table 4
- Error
- ± 520 SEM, n = 2
- Emax
- 17.4 ± 1.1%
Also reported to act here
Substances reported to act here, without a displayed value.
Values are published numbers in nM per organism. Different assays, species and receptor preparations are not directly interchangeable, and a value does not establish clinical potency or safety.